Literature DB >> 2511911

Slow release nifedipine plus atenolol in chronic stable angina pectoris.

V F Challenor1, D G Waller, A G Renwick, C F George.   

Abstract

1. The effects of adding slow release nifedipine in doses of 20 mg and 40 mg twice daily to atenolol therapy (50 mg twice daily) were assessed in 18 patients with chronic stable angina. 2. The addition of the lower dose of nifedipine to atenolol did not significantly alter the weekly consumption of glyceryl trinitrate or the mean number of anginal attacks as assessed by diary cards. However, 2 h after dosing there was a significant prolongation during stress testing in the time to onset of both 1 mm ST depression on the ECG (by 28%) and to angina (by 37%) compared with atenolol alone, but no benefit was apparent by 12 h after dosing. 3. At a dose of 40 mg twice daily, nifedipine significantly reduced glyceryl trinitrate consumption by 25% and the number of anginal attacks by 36%. The times to onset of ST depression and angina were increased by 37% and 55% respectively at 2 h and by 24% and 26% respectively 12 h after dosing. 4. Analysis of the frequency distribution of anginal attacks showed decreasing efficacy with time after administration of nifedipine. The overall results also suggest a relationship between efficacy and the plasma nifedipine concentration, with a mean 20% improvement in time to development of angina occurring at a nifedipine plasma concentration of approximately 30-40 ng ml-1. 5. In conclusion, the reduction of effort-related angina by nifedipine is related to its plasma concentration and the effective duration of action of the 20 mg slow release formulation is less than 12 h.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511911      PMCID: PMC1380010          DOI: 10.1111/j.1365-2125.1989.tb03536.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

2.  [Anti-ischemic effect of nifedipine in delayed-action form. Results of a double-blind, randomized, crossover, placebo-controlled acute study].

Authors:  U Brügmann; R Blasini; W Rudolph
Journal:  Herz       Date:  1983-08       Impact factor: 1.443

Review 3.  Slow channel blockers.

Authors:  J O Covinsky; S C Hamburger
Journal:  South Med J       Date:  1983-01       Impact factor: 0.954

4.  The use of propranolol and nifedipine in the medical management of angina pectoris.

Authors:  K M Fox; A Jonathan; A P Selwyn
Journal:  Clin Cardiol       Date:  1981-05       Impact factor: 2.882

5.  Dose response effectiveness of propranolol for the treatment of angina pectoris.

Authors:  E L Alderman; R O Davies; J J Crowley; M G Lopes; J Z Brooker; J P Friedman; A F Graham; H J Matlof; D C Harrison
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

6.  Improved exercise tolerance after propranolol, diltiazem or nifedipine in angina pectoris: comparison at 1, 3 and 8 hours and correlation with plasma drug concentration.

Authors:  B R Chaitman; P Wagniart; A Pasternac; G Brevers; J M Scholl; J Lam; M Methe; R J Ferguson; M G Bourassa
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

7.  Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine.

Authors:  O Banzet; J N Colin; M Thibonnier; E Singlas; J M Alexandre; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Treatment of angina pectoris with nifedipine: importance of dose titration.

Authors:  J Deanfield; C Wright; K Fox
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-07

9.  The combination of nifedipine and propranolol in the management of patients with angina pectoris.

Authors:  A C Tweddel; J M Beattie; R G Murray; I Hutton
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

10.  Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial.

Authors:  L G Sherman; C S Liang
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

View more
  4 in total

1.  Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

Authors:  S Wieshammer; M Hetzel; U Barnikel; M Höher; H Seibold; M Kochs; V Hombach
Journal:  Klin Wochenschr       Date:  1991-09-16

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

4.  A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.

Authors:  K M Donaldson; K D Dawkins; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.